Mustang Bio Inc. (MBIO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

MBIO carries an RQD Score of 39 and a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the fundamental cash engine scores 4 / 20 (ROIC -35%; FCF yield 0%), indicating that the business is not currently generating returns on capital or free cash flow. The whale 13F flow pillar scores 10 / 20 for institutional accumulation and options positioning, a middling reading. The insider conviction pillar scores 5 / 20 on SEC Form 4 and Congressional PTR cluster flow, signaling weak insider-side support. The macro regime fit pillar scores 10 / 20, with a Beta of 1.0 and a sector sensitivity profile. The forensic balance sheet pillar scores 10 / 20, reflecting an Altman Z of 2.5, a Piotroski F of 2/9, and a Debt/Equity of 0.5.

For a prospective investor, the upside case rests almost entirely on whether the company can convert its cash position into a durable operating path, since current cash flow and returns are negative. Valuation tradeoffs are sharp: with a market capitalization of $3.0M and a share price of 0.39, the equity is priced at a very small scale relative to the operating losses recorded in the SEC financials. The rating's weakest pillars point to the core risks of dilution, continued cash burn, and limited institutional or insider conviction. Any reading of the stock should weigh these structural factors against the short-term price momentum shown in the market data.

Mustang Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. The SEC financials report revenue of — across the FY 2023, FY 2024, and FY 2025 periods, so the company is not generating reported revenue in the provided data. Beyond sector, industry, and exchange classification, further business detail is —

Operating and net losses narrowed from -$51.6M in FY 2023 to -$1.9M in FY 2025, and reported cash rose from $6.8M in FY 2024 to $17.3M in FY 2025. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, . Debt/Equity is 0.5, and the SEC table lists debt as N/A for each period.

• 🐂 Primary Bull Case: Reported cash rose to $17.3M in FY 2025 while net loss narrowed to -$1.9M from -$51.6M in FY 2023. With Fundamental Cash Engine at 4/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 12/20, sustained execution supports upside toward the top of the $0.35 – $1.45 52-week range.
• 🐻 Primary Bear Case: With a 39 RQD score, ROIC of -35%, zero FCF yield, and a $0.39 price amid a Nasdaq bid-price reprieve, the balance sheet and flow profile look vulnerable. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore —

• Key Question #1: What products or clinical programs generate the company's R&D spending, and what is their development stage?
• Key Question #2: What is the company's current debt obligation, since the SEC financials list debt as N/A?
• Key Question #3: What is the cash runway implied by FY 2025 cash of $17.3M against FY 2025 free cash flow of -$5.3M?